Positive experience of Intraperitoneal Chemotherapy followed by Intravenous Chemotherapy in Heavily Pretreated Patients with Suboptimal Residual Ovarian Cancer and Primary Peritoneal Cancer
Restricted accessResearch articleFirst published online November, 2010
Positive experience of Intraperitoneal Chemotherapy followed by Intravenous Chemotherapy in Heavily Pretreated Patients with Suboptimal Residual Ovarian Cancer and Primary Peritoneal Cancer
To assess feasibility and toxicity of intraperitoneal administration of cisplatin and paclitaxel, followed by intravenous chemotherapy in pretreated patients with suboptimal ovarian cancer (residuum >1 cm) or primary peritoneal tumor, and suffering from ascites and/or intestinal obstruction.
Methods
Fourteen relapsed ovarian cancer patients, 5 of whom were platinum sensitive (platinum-free interval >6 mo), 7 platinum-resistant (platinum-free interval <6 mo), and 2 platinum-refractory, received one cycle of intraperitoneal cisplatin, 100 mg/m2 on day 1, and two cycles of intraperitoneal paclitaxel, 120 mg/m2 on days 8 and 14. Intravenous chemotherapy was administrated 4 weeks following the last intraperitoneal paclitaxel instillation. Blood and peritoneal fluid samples were harvested at 0, 1, 4 and 24 h after ending paclitaxel delivery to guarantee proper tumor exposure and patient safety.
Results
Intraperitoneal cisplatin determined 6 cases of vomiting grade 1–2 (40% of the morbidity). Intraperitoneal paclitaxel was associated with 6 events of grade 1–2 abdominal pain; the only grade 4 toxicity was one case of neutropenia and one of mucositis. Ascites decreased in 11 patients: the median time to first need for paracentesis was 5 months, compared to a median baseline paracentesis of 4 weeks. Three intestinal normalizations were obtained. The median overall survival was 10 months for our cohort of patients. Intraperitoneal paclitaxel clearance was significantly higher in patients with suboptimal tumor and symptomatic disease than in patients with smaller residual masses and without ascites (P = 0.004).
Conclusions
Intraperitoneal treatment was feasible, and enhanced response to the following intravenous chemotherapy was seen in these patients. Free full text available at www.tumorionline.it
JemalA., SiegelR., WardE., HaoY., XuJ., ThunM.J.: Cancer statistics. CA Cancer J Clin, 59: 225–249, 2009.
2.
BonnefoiH., A'HernR.P., FisherC., MacfarlaneV., BartonD., BlakeP., ShepherdJ.H., GoreM.E.: Natural history of stage IV epithelial ovarian cancer. J Clin Oncol, 17: 767–775, 1999.
3.
HeintzA.P., OdicinoF., MaisonneuveP., QuinnM.A., BenedetJ.L., CreasmanW.T., NganH.Y., PecorelliS., BellerU.: Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 95 Suppl: S161–192, 2006.
BergmanF.: Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand, 45: 211–231, 1966.
9.
DedrickR.L., MyersC.E., BungayP.M., DeVita VTJ.r.: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep, 62: 1–11, 1978.
10.
MarkmanM., KennedyA., WebsterK., PetersonG., KulpB., BelinsonJ.: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol, 19: 1901–1905, 2001.
11.
McClayE.F., HowellS.B.: A review: intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol Oncol, 36: 1–6, 1990.
12.
HowellS.B., PfeifleC.L., WungW.E., OlshenR.A., LucasW.E., YonJ.L., GreenM.: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med, 97: 845–851, 1982.
13.
TrimbleE.L., ChristianM.C.: National Cancer Institute -United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer, 18 Suppl1: 26–28, 2008.
14.
ArmstrongD.K., BundyB., WenzelL., HuangH.Q., BaergenR., LeleS., CopelandL.J., WalkerJ.L., BurgerR.A.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med, 354: 34–43, 2006.
15.
AlbertsD.S., LiuP.Y., HanniganE.V., O'TooleR., WilliamsS.D., YoungJ.A., FranklinE.W., Clarke-PearsonD.L., MalviyaV.K., DuBeshterB.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med, 335: 1950–1955, 1996.
MarkmanM., BundyB.N., AlbertsD.S., JowlerJ.M., Clark-PearsonD.L., CarsonL.F., WadlerS., SickelJ.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol, 19: 1001–1007, 2001.
18.
PretoriusR.G., HackerN.F., BerekJ.S., FordL.C., HoescheleJ.D., ButlerT.A., LagasseL.D.: Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep, 67: 1085–1092, 1983.
DeGregorioM.W., LumB.L., HolleranW.M., WilburB.J., SikicB.I.: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol, 18: 235–238, 1986.
21.
ElferinkF., van der VijghW.J., KleinI., ten Bokkel HuininkW.W., DubbelmanR., McVieJ.G.: Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol, 21: 57–60, 1988.
22.
FujiwaraK., SakuragiN., SuzukiS., YoshidaN., MaehataK., NishiyaM., KoshidaT., SawaiH., AotaniE., KohnoI.: Firstline intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol, 90: 637–643, 2003.
23.
MiyagiY., FujiwaraK., KigawaJ., ItamochiH., NagaoS., AotaniE., TerakawaN., KohnoI.: Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin – a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol, 99: 591–596, 2005.
NagaoS., FujiwaraK., OhishiR., NakanishiY., IwasaN., ShimizuM., GotoT., ShimoyaK.: Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. Int J Gynecol Cancer, 18: 1210–1214, 2008.
26.
FuiwaraK., NagaoS., KigawaJ., NomaJ., AkamatsuN., MiyagiY., NumaF., OkadaM., AotaniE.: Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecologic cancer study group study. Int J Gynecol Cancer, 19: 834–837, 2009.
27.
NicolettoM.O., FalciC., PianaltoD., ArtioliG., AzzoniP., De MasiG., FerrazziE., PerinA., DonachM., ZoliW.: Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol, 100: 318–323, 2006.
28.
YesavageJ.A., BrinkT.L., RoseT.L., LumO., HuangV., AdeyM., LeirerV.O.: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res, 17: 37–49, 1982.
29.
McNairD.M., LorrM., DropplemanL.F.: Profile of mood states manual.Educational and Industrial Testing Service, San Diego, CA, 1971.
30.
ReijneveldS.A., SpijkerJ., DijkshoornH.: Katz’ ADL index assessed functional performance of Turkish, Moroccan, and Dutch elderly. J Clin Epidemiol, 60: 382–388, 2007.
31.
LawtonM.P., BrodyE.M.: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist, 9: 179–186, 1969.
32.
CrumR.M., AnthonyJ.C., BassettS.S., FolsteinM.F.: Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA, 269: 2386–2391, 1993.
33.
WHO Handbook for reporting results of Cancer Treatment. WHO offset publication No. 48, Neoplasma, 20: 37–46, 1980.
34.
FranklinH.R., SimonettiG.P., DubbelmanA.C., ten Bokkel HuininkW.W., TaalB.G., WigboutG., MandjesI.A., DalesioO.B., AaronsonN.K.: Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol, 5: 113–117, 1994.
